Articles with public access mandates - Ferdinando NicolettiLearn more
Not available anywhere: 6
Akt as a therapeutic target in cancer
LS Steelman, KM Stadelman, WH Chappell, S Horn, J Bäsecke, ...
Expert opinion on therapeutic targets 12 (9), 1139-1165, 2008
Mandates: US National Institutes of Health
Diverse roles of GSK-3: Tumor promoter–tumor suppressor, target in cancer therapy
JA McCubrey, NM Davis, SL Abrams, G Montalto, M Cervello, J Basecke, ...
Advances in biological regulation 54, 176-196, 2014
Mandates: Government of Italy
Emerging RAF inhibitors
JA McCubrey, LS Steelman, SL Abrams, WH Chappell, S Russo, R Ove, ...
Expert opinion on emerging drugs 14 (4), 633-648, 2009
Mandates: US National Institutes of Health
Orally delivered all-trans-retinoic acid-and transforming growth factor-β-loaded microparticles ameliorate type 1 diabetes in mice
I Koprivica, D Gajic, T Saksida, E Cavalli, D Auci, S Despotovic, ...
European journal of pharmacology 864, 172721, 2019
Mandates: Ministry of Education, Science and Technological Development of the Republic …
Apotransferrin inhibits interleukin-2 expression and protects mice from experimental autoimmune encephalomyelitis
T Saksida, D Miljkovic, G Timotijevic, I Stojanovic, S Mijatovic, P Fagone, ...
Journal of neuroimmunology 262 (1-2), 72-78, 2013
Mandates: Government of Italy
Rationale for Targeting of YY1 in Drug-resistant Leukemias
JA McCubrey, SL Abrams, WH Chappell, LS Steelman, G Ligresti, N Vella, ...
Onco Therapeutics 1 (1-2), 2010
Mandates: US National Institutes of Health
Available somewhere: 36
Natural products in drug discovery: advances and opportunities
AG Atanasov, SB Zotchev, VM Dirsch, CT Supuran
Nature reviews Drug discovery 20 (3), 200-216, 2021
Mandates: US National Institutes of Health, Austrian Science Fund, Australian Research …
GSK-3 as potential target for therapeutic intervention in cancer
JA McCubrey, LS Steelman, FE Bertrand, NM Davis, M Sokolosky, ...
Oncotarget 5 (10), 2881, 2014
Mandates: Government of Italy
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, G Montalto, ...
Oncotarget 3 (9), 954, 2012
Mandates: Fondazione Cariplo
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance
JA McCubrey, LS Steelman, WH Chappell, SL Abrams, RA Franklin, ...
Oncotarget 3 (10), 1068, 2012
Mandates: Fondazione Cariplo
The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients
AM Martelli, C Evangelisti, F Chiarini, JA McCubrey
Oncotarget 1 (2), 89, 2010
Mandates: US National Institutes of Health
Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy
LS Steelman, RA Franklin, SL Abrams, W Chappell, CR Kempf, J Bäsecke, ...
Leukemia 25 (7), 1080-1094, 2011
Mandates: US National Institutes of Health
Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention
NM Davis, M Sokolosky, K Stadelman, SL Abrams, M Libra, S Candido, ...
Oncotarget 5 (13), 4603, 2014
Mandates: Government of Italy
Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention
JA McCubrey, LS Steelman, FE Bertrand, NM Davis, SL Abrams, ...
Leukemia 28 (1), 15-33, 2014
Mandates: Government of Italy
Targeting the leukemic stem cell: the Holy Grail of leukemia therapy
N Misaghian, G Ligresti, LS Steelman, FE Bertrand, J Bäsecke, M Libra, ...
Leukemia 23 (1), 25-42, 2009
Mandates: US National Institutes of Health
Effects of resveratrol, curcumin, berberine and other nutraceuticals on aging, cancer development, cancer stem cells and microRNAs
JA McCubrey, K Lertpiriyapong, LS Steelman, SL Abrams, LV Yang, ...
Aging (Albany NY) 9 (6), 1477, 2017
Mandates: Government of Italy
Effects of mutations in Wnt/β-catenin, hedgehog, Notch and PI3K pathways on GSK-3 activity—Diverse effects on cell growth, metabolism and cancer
JA McCubrey, D Rakus, A Gizak, LS Steelman, SL Abrams, ...
Biochimica et Biophysica Acta (BBA)-Molecular Cell Research 1863 (12), 2942-2976, 2016
Mandates: Government of Italy
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy
SL Abrams, LS Steelman, JG Shelton, EWT Wong, WH Chappell, ...
Cell cycle 9 (9), 1781-1791, 2010
Mandates: US National Institutes of Health
The therapeutic potential of mTOR inhibitors in breast cancer
LS Steelman, AM Martelli, L Cocco, M Libra, F Nicoletti, SL Abrams, ...
British journal of clinical pharmacology 82 (5), 1189-1212, 2016
Mandates: Government of Italy
Roles of GSK-3 and microRNAs on epithelial mesenchymal transition and cancer stem cells
JA McCubrey, TL Fitzgerald, LV Yang, K Lertpiriyapong, LS Steelman, ...
Oncotarget 8 (8), 14221, 2017
Mandates: Government of Italy
Publication and funding information is determined automatically by a computer program